Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 400 versus VISIPAQUE 320.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 400 versus VISIPAQUE 320.
CONRAY 400 vs VISIPAQUE 320
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiocontrast agent that attenuates X-rays by blocking their passage, thereby enhancing radiographic contrast in imaging procedures.
Iodinated nonionic radiocontrast agent that attenuates X-rays and enhances vascular and tissue contrast.
0.5-1.0 mL/kg (up to 150 mL total) intravenously, maximum 150 mL per procedure.
Intravascular administration: Adult dose is 50-150 mL (16-48 g iodine) intravenously as a bolus or infusion, depending on the procedure. For CT imaging, typical dose is 75-150 mL at 1-3 mL/sec.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged significantly.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. Clinically, clearance is prolonged in renal impairment, requiring dose adjustment.
Primarily renal: >95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion: negligible (<1%).
Primarily renal via glomerular filtration; approximately 95% of the dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent